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1607-551X/Copyright ª 2015, KaohsiuAbstract Venous thromboembolism (VTE) is one of the severe complications of total hip ar-
throplasty (THA) and total knee arthroplasty (TKA). The incidence of VTE could be reduced if
preventive antithrombotic medicines are used; however, the incidence of bleeding may in-
crease. Rivaroxaban is a factor Xa inhibitor that prevents VTE after THA or TKA. This study
is designed to confirm the efficacy and safety of rivaroxaban in Taiwan. This is a retrospective
database study based on the data of 6996 patients provided by the Taiwan National Health In-
surance Research Database from 2008 to 2012. The data included the number of prescription,
the cost of prescription, and case number for patients treated with antithrombotic agents for
the prevention or treatment of joint arthroplasty complications (including THA, TKA, partial
hip arthroplasty, revision THA and TKA), and the incidence of thrombosis and hemorrhage from
year 2008 to 2012. The overall postoperative VTE rate was 0.49%. Compared with other antith-
rombotic drugs, rivaroxaban and heparin analogs can reduce the percentage of thrombosis. We
also found that the expenditure and hospitalization was less in the rivaroxaban group than ineclare no conflicts of interest.
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Rivaroxaban in preventing venous thromboembolism 535the heparin analogs group. Because some benefits of rivaroxaban were found in our study,
further cost-effective and drug safety studies are warranted. It is important to consider the
cost-effective principle for the use of antithrombotic drugs in preventing thromboembolic
complications after total joint arthroplasty.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Venous thromboembolism (VTE) frequently occurs after
total joint replacement. The incidence of VTE may be
reduced to 50% if antithrombotic drugs are used during
total hip arthroplasty (THA) or total knee arthroplasty (TKA)
[1]. In a large epidemiological study conducted in an Asian
group, the incidence of deep vein thrombosis (DVT) was 41%
if antithrombotic drugs were not used after THA or TKA
surgery [2]. In another study in the United States including
250,000 THA patients and 600,000 TKA patients, it was
found that 0.9% of THA patients and 0.7% of TKA patients
had symptomatic DVT, and 0.3% of those patients devel-
oped serious pulmonary embolism and were subsequently
readmitted for adverse medical problems [3]. According to
the current therapeutic guidelines suggested by the Amer-
ican College of Chest Physicians, antithrombotic drugs
should be regularly given for the prevention of DVT in pa-
tients who have undergone THA or TKA [4,5]. The American
Academy of Orthopedic Surgeons also suggested that the
therapeutic rules should be based on individual case
assessment to determine the best special preventive pro-
gram in total joint arthroplasty patients with a minimum of
10 days [6]. It was also suggested by the National Institute
for Clinical Excellence in 2010 that the updated guidelines
for the prevention of DVT and pulmonary embolism after
total joint arthroplasty should include the use of antith-
rombotic drugs such as unfractionated heparin, low mo-
lecular weight heparin, fondaparinux, and rivaroxaban [7].
One serious complication of frequently used antith-
rombotic drugs (such as aspirin, warfarin, or heparin) is
hemorrhage. Clinicians should consider the possibility of
hemorrhage if a patient receiving antithrombotic therapy
develops any uncertain clinical problem. When a patient
receives warfarin therapy, the status of hemorrhage may
not only relate to the values of Prothrombin time/Inter-
national ratio (PT/INR) but also the underlying disease.
Careful consideration should be given when prescribing
warfarin to DVT patients to avoid the possibility of heparin-
induced thrombocytopenia. It may lead to amputation or
even death when use of warfarin is initiated right before
the termination of heparin owing to the occurrence of
heparin-induced thrombocytopenia [8].
Rivaroxaban is an antithrombotic drug whose mechanism
of action is direct inhibition of the coagulation factor Xa.
The first dose of rivaroxaban (10 mg) is usually given about
6e10 hours after the surgery when the bleeding has
stopped; then it is taken once daily. It is suggested to give a
whole course of 14 days after TKA and 35 days after THA
[6]. The best advantage of using rivaroxaban is that it is notnecessary to monitor the coagulation status, such as PT and
Partial prothrombin time (PTT). Moreover, the efficacy of
rivaroxaban is not affected by meal intake, so it can be
taken prior to or after meals. In a large research series, it
has been found that the incidence of VTE was reduced to
49% in Europe and 31.4% in the United States, and the
incidence is 70e79% lower than that recorded for enox-
aparin and the incidence of bleeding is the same as that of
enoxaparin [9e13].
Using the Taiwan National Health Insurance Research
Database (NHIRD), a nationwide database with epidemio-
logic information on total joint arthroplasty, this study
aimed to confirm the efficacy and the safety of antith-
rombotic agents, including the factor Xa inhibitor rivarox-
aban, for the prevention of VTE after total joint
arthroplasty in Taiwan.
Materials and methods
Data sources
Since 1995, Taiwan has implemented an only-payer Na-
tional Health Insurance (NHI) Program to pay for the
healthcare needs of all residents. All citizens have to
participate in the NHI Program, so the coverage rate was
more than 99.9% with more than 23.2 million individuals
enrolled [14]. The National Health Research Institutes
(NHRI) in Taiwan maintains the NHIRD. The database con-
tains comprehensive information on insured persons: de-
mographic data, diagnostic codes, dates of clinical visits
and hospitalizations, length of hospital stay, details of
prescriptions, procedures/surgeries, and expenditures,
which were for research purposes only. This dataset was a
randomized sampling distribution from about 23.2 million
people, with comprehensive data covering all medications
of 1 million people, and then all medical records were
followed from 2008 to 2012.
Study population
The study was approved by the Institutional Review Board
(KMUH-IRB-2013029). This study included 6996 patients who
received arthroplasty from April 1, 2008 to September 30,
2012, including revision of THA, revision of TKA, partial hip
arthroplasty, THA, and TKA in a database of 1 million
people. Patients with thrombotic or hemorrhagic diseases
within the past 90 days relating to arthroplasty and who
have used antithrombotic drugs in clinics were excluded.
The data include all medications up to 3 months after the
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anticoagulants they took. Group 1 patients took rivarox-
aban. Group 2 patients took heparin analogs including
heparin or enoxaparin. Group 3 consisted of patients who
took anticoagulants other than rivaroxaban or heparin an-
alogs. Patients in Group 4 did not take any anticoagulants
at all.
Outcome measurement
Outcome measures included the efficacy and safety of
antithrombotic drugs for total joint arthroplasty. The effi-
cacy assessment included the analyses of total hospitali-
zation days, costs of drugs, costs of medical care, and
number of posthospitalization visits to orthopedic clinics,
as well as refills of rivaroxaban posthospitalization visits to
orthopedic clinics. The safety assessment focused on the
incidence of thrombotic and hemorrhagic events based on
their diagnostic codes. The thrombotic event codes were as
follows: 433e436 cerebrovascular accident and acute ce-
rebral vascular disease; 437.9 cerebrovascular disease;
453.8 deep vein thrombosis; 415.1x pulmonary embolism
and 444e444.9 artery thrombosis disease. The hemorrhagic
event codes were as follows: 430 subarachnoid hemor-
rhage; 431 intracerebral hemorrhage; cerebral hemor-
rhage; 432.1 subdural hemorrhage; 432.9 intracranial
hemorrhage; 578.0 hematemesis; 578.9 upper gastrointes-
tinal bleeding; 599.7 hematuria; 626.2 menorrhagia; 627.1
postmenopausal bleeding; 719.10 hemarthrosis; 786.3 he-
moptysis; 784.7 epistaxis; 4590 unknown bleeding; 423
epicardium bleeding and 9981, 71910, 71916, 71917 surgical
hemarthrosis or bleeding.
Statistical analysis
The categorical variables of operation diagnostic codes,
disease codes, and types of antithrombotic drugs with sin-
gle or combined use were expressed as case numbers and
percentages. The continuous variables were expressed as
means  standard error. The Chi-square test was applied toTable 1 Comparisons of characteristics, medical costs, and eve
Rivaroxaban Heparin
Number 70 167
Age (y) 67.3  1.37 72.7 
Sex (M/F) 11/59 61/106
Charlson index 3.23  0.123 3.59 
Cost of drugs during
hospitalization (NTD)
3467  404 7068 
Cost of medical care during
hospitalization (NTD)
120,927  3798 143,958
Hospitalization days 8.5  0.42 11.4 
Admission during the same year 1.12  0.038 1.07 
Readmission rate 90 d after
discharge (rate)
2 (2.86%) 1 (0.60
Thrombosis event (rate) 1 (1.43%) 2 (1.20
Hemorrhage event(rate) 3 (4.29%) 10 (5.9
NTD Z New Taiwanese dollar.analyze the differences in age, sex, and disease code, be-
tween the groups. Two-tailed t test and analysis of variance
were used to analyze the differences in total hospitaliza-
tion days and Charlson comorbidity index (CCI) [15] be-
tween groups. A value of p < 0.05 was considered
statistically significant. The efficacy and safety of drugs
were assessed with the total case numbers and incidences
(percentages) of thrombosis and hemorrhage expressed as
mean  standard deviation, and the relative risks for the
use of rivaroxaban and other antithrombotic drugs. The
comparison between treatment with and without rivarox-
aban, based on age, sex, hospitalization days, admission
disease code, and CCI, were further analyzed with logistic
regression if p < 0.05. The adjusted relative risks were used
for the analysis of thrombosis and hemorrhage. All analyses
were conducted using SAS version 9.1.3 and SPSS 20.
Results
Analysis during hospitalization
As shown in Table 1, the data for the treatment were
compared in 2008 to 2012. It was found that age (Group 1:
67.3  1.37 vs. Group 2: 72.7  0.82 vs. Group 3:
71.4  0.65 vs. Group 4: 70.5  0.15, p < 0.01) and CCI
(Group 1: 3.23  0.123 vs. Group 2: 3.59  0.084 vs. Group
3: 3.46  0.055 vs. Group 4: 3.38  0.013, pZ 0.015) were
significantly lower in Group 1 than in the other groups.
Hospitalization days (Group 1: 8.5  0.42 vs. Group 2:
11.4  0.73 vs. Group 3: 8.8  0.43 vs. Group 4: 8.3  0.06,
p < 0.01) and cost of medical care during hospitalization
(Group 1: 120,927  3798 vs. Group 2: 143,958  6345 vs.
Group 3: 121,049  2870 vs. Group 4: 113,810  612,
p < 0.01) were significantly higher in Group 2. There was no
significance in cost of drugs during hospitalization, admis-
sion during the same year, and readmission rate 90 days
after discharge.
By contrast, the incidence of hemorrhage in Groups 1
and 2 was higher compared with that in Groups 3 and 4
(Group 1: 4.29% vs. Group 2: 5.99% vs. Group 3: 1.49% vs.nts during hospitalization.
analogs Others None p
268 6491
0.82 71.4  0.65 70.5  0.15 <0.01
75/193 2082/4409 <0.01
0.084 3.46  0.055 3.38  0.013 0.015
1371 3277  406 2650  432 0.375
 6345 121,049  2870 113,810  612 <0.01
0.73 8.8  0.43 8.3  0.06 <0.01
0.019 1.05  0.013 1.07  0.003 0.258
%) 6 (2.24%) 213 (3.28%) 0.196
%) 9 (3.36%) 22 (0.34%) <0.01
9%) 4 (1.49%) 121 (1.86%) <0.01
Rivaroxaban in preventing venous thromboembolism 537Group 4: 1.86%, p < 0.01). The incidence of thrombosis in
Group 3 was higher, but lower in Group 4 (Group 1: 1.45%
vs. Group 2: 1.20% vs. Group 3: 3.36% vs. Group 4: 0.34%,
p < 0.01).Analysis at clinics after hospitalization
During the follow-up at clinics 14 days after discharge,
most patients (91.9%) did not receive any coagulant. Only
459 patients took anticoagulants. In these patients, 430
patients took anticoagulants other than rivaroxaban and
heparin analogs. Only seven patients took rivaroxaban,
and 22 patients took heparin analogs (Table 2). It was
found that age (Group 1: 67.9  3.4 vs. Group 2:
67.7  3.1 vs. Group 3: 74.6  0.4, vs. Group 4: 70.5  0.2,
p < 0.01) and CCI (Group 1: 3.43  0.3 vs. Group 2:
3.32  0.24 vs. Group 3: 3.7  0.03 vs. Group 4:
3.35  0.01, p < 0.01) were significantly higher in Group 3
than in other groups. Drug expenditure (Group 1:
2579  462 vs. Group 2: 9012  3877 vs. Group 3:
2299  124 vs. Group 4: 1201  57, p < 0.01) was highest
in Group 2 and lowest in Group 4. Medical expenditure
(Group 1: 4422  818 vs. Group 2: 17,877  4021 vs. Group
3: 4190  168 vs. Group 4: 2754  65, p < 0.01) showed a
similar trend to drug expenditure. The highest thrombosis
ratio was found in the rivaroxaban group (42.9%), but
there were no bleeding events in both rivaroxaban and
heparin analog groups.
We further analyzed the data at clinics from 2 weeks to
3 months after hospital discharge (Table 3). We found that
age (Group 1: 69.4  2.9 vs. Group 2: 69.1  2.4 vs. Group
3: 74.7  0.4, vs. Group 4: 70.7  0.2, p < 0.01) wasTable 3 Comparison of expenditure and adverse events from 2
Rivaroxaban Heparin
Age (y) 69.4  2.9 69.1 
Charlson index 3.8  0.2 3.43 
Drug expenditure (NTD) 2048  192 8653 
Medical expenditure (NTD) 3521  822 19,374
Clinical visit (times) 6.2  1.53 3.91 
Thrombosis event (yes/total) (ratio) 2/5 (40%) 1/23 (4
Bleeding event (yes/total) (ratio) 0/5 (0) 0/23 (0
NTD Z New Taiwanese dollar.
Table 2 Comparison of expenditure and adverse events 2 week
Rivaroxaban Heparin
Age (y) 67.9  3.4 67.7 
Charlson index 3.43  0.3 3.32 
Drug expenditure (NTD) 2579  462 9012 
Medical expenditure (NTD) 4422  818 17,877
Clinical visit (times) 1.29  0.18 1.32 
Thrombosis event (yes/total) (ratio) 3/7 (42.9%) 1/22 (4
Bleeding event (yes/total) (ratio) 0/7 (0) 0/22 (0
NTD Z New Taiwanese dollar.significantly higher in Group 3 than in other groups. CCI
(Group 1: 3.8  0.2 vs. Group 2: 3.43  0.22 vs. Group 3:
3.73  0.04 vs. Group 4: 3.37  0.01, p < 0.01) was higher
in Groups 1 and 3. Drug expenditure (Group 1: 2048  192
vs. Group 2: 8653  3722 vs. Group 3: 2377  125 vs.
Group 4: 1253  59, p < 0.01) was highest in Group 2 and
lowest in Group 4. Medical expenditure (Group 1:
3521  822 vs. Group 2: 19,374  3677 vs. Group 3:
4228  167 vs. Group 4: 2819  67, p < 0.01) showed the
same trend as drug expenditure. The highest thrombosis
ratio was also found in the rivaroxaban group (40%), but
there were no bleeding events in both rivaroxaban and
heparin analog groups.Discussion
The current national insurance payment system for total
joint arthroplasty in Taiwan is based on diagnosis-related
groups (DRGs). Under DRGs, medical expenses paid to the
hospital were fixed by the same diagnosis and procedure.
Therefore, it is critical to reduce the total days of hospi-
talization and the costs of laboratory examinations
[16e18]. As such, the diagnosis of VTE may be easily
ignored. Furthermore, many orthopedic surgeons may
worry about the complications of bleeding during surgery,
and this may cause the possibility of wound complications
[19], so that hospitalization days may be increased. Owing
to the difficulty involved in diagnosing VTE in orthopedic
departments, the confirmed diagnosis requires consulta-
tion with cardiologists or radiologists for further diagnostic
tests. Therefore, the total number and dates of antith-
rombotic drug prescription are reduced if there is noweeks to 3 months after discharge from hospital.
analogs Others None p
2.4 74.7  0.4 70.7  0.2 <0.01
0.22 3.73  0.04 3.37  0.01 <0.01
3722 2377  125 1253  59 <0.01
 3677 4228  167 2819  67 <0.01
0.54 5.11  0.18 3.74  0.04 <0.01
.3%) 71/437 (16.2%) 326/4938 (6.6%) <0.01
) 58/437 (13.3%) 519/4938 (10.5%) 0.087
s after discharge from hospital.
analogs Others None p
3.1 74.6  0.4 70.5  0.2 <0.01
0.24 3.7  0.03 3.35  0.01 <0.01
3877 2299  124 1201  57 <0.01
 4021 4190  168 2754  65 <0.01
0.12 2.05  0.06 1.68  0.01 <0.01
.5%) 70/430 (16.3%) 337/5166 (6.5%) <0.01
) 57/430 (13.3) 523/5166 (10.1%) 0.056
Table 4 Risk of hemorrhage during hospitalization.
Odds ratio p
Male (female Z 1) 1.487 0.025
Antithrombotic drugs
(no antithrombotic drugs Z 1)
1.868 0.018
Rivaroxaban (other and no and
antithrombotic drugs Z 1)
1.667 0.015
538 Y.-C. Mao et al.adequate diagnosis. In a previous National Health Insur-
ance database study, Wu et al. [20] reported that the
occurrence rate of overall postoperative VTE was 0.44%
during 2002 to 2006; a total of 114,026 patients underwent
hip (N Z 61,460) or knee (N Z 52,566) replacement sur-
geries [20]. In this study, the overall postoperative VTE was
0.49% during 2008 to 2012. Our results were similar to the
results of previous studies conducted in Taiwan even
though the sample size and sampling methods used are not
the same.
Hospital-acquired events were estimated by applying
specific risk frequencies for developing VTE to the surgical
and medical at-risk populations, according to whether or
not they were receiving VTE prophylaxis [21]. In this study,
we have found that prescription of antithrombotic drugs for
total joint replacement was only 7.1% between 2008 and
2012. Once orthopedic surgeons have prescribed antith-
rombotic agents in thrombosis prevention after THA and
TKA, they must add the diagnostic code of thrombosis for
the reimbursement concerned. The likelihood of throm-
bosis diagnosis was greatly reduced among orthopedic sur-
geons who were not aware about DVT diagnosis and
prevention, which may have led to the minimal use of
antithrombotic drugs. The thrombosis code during hospi-
talization was checked by a code specialist according to the
data found in the charts. This would lead to a significantly
higher rate of thrombosis diagnosis in hospitalized patients
treated with rivaroxaban, heparin analogs, or other
antithrombotic drugs compared with those who did not
receive antithrombotic drugs (Group 1: 1.45% vs. Group 2:
1.20% vs. Group 3: 3.36% vs. Group 4: 0.34%, p < 0.01).
Theoretically, patients who did not receive antithrombotic
drug treatment should have the highest incidence in
thrombosis, but the results showed the opposite. Those
who did not use antithrombotic medication may have been
less likely to describe the symptoms and diagnosis of DVT,
which in turn may have led to the very low incidence of
thrombosis in the group that did not receive antithrombotic
drugs. The phenomenon was more obvious in the follow-up
data at clinics. There was an unreasonably high incidence
of thrombosis incidence in the rivaroxaban group, which
was recorded as 42.9% (3/7) and 40% (2/5). The incorrect
diagnostic code is a detrimental drawback in the database
study.
During hospitalization, heparin analogs led to high drug
and hospitalization expenditure with longer hospitaliza-
tion, but they had the least readmission rate 90 days after
discharge. The drug and hospitalization expenditures were
similar in rivaroxaban and other drug groups; however, the
patients in the rivaroxaban group were younger compared
with patients in the other groups, which translated to
certain advantages: less drug and hospitalization expendi-
tures and lower number of adverse events such as throm-
bosis and hemorrhage. Compared with other drug groups,
rivaroxaban and heparin analog groups showed reduced
thrombosis incidence with obviously more bleeding effects.
Regarding the follow-up results at clinics, heparin ana-
logs led to high drug and medical expenditures compared
with other groups, similar to the trend observed during
hospitalization. In other drug groups, the patients were
much older than their counterparts in all other groups withhigher CCI values, which may have led to more visits to
clinics. There was also a higher thrombosis incidence rate in
other drug groups when compared with the heparin analog
group. We therefore infer that heparin analogs had an ef-
fect in reducing thrombosis; we do not exactly know how
age and higher CCI in other drug groups affected the inci-
dence of thrombosis. Because the incidence of thrombosis
in the rivaroxaban group was unreasonably high, we infer
that the results may be somewhat misleading, because the
use of rivaroxaban should have the code of thrombosis for
reimbursement.
Rivaroxaban, a factor Xa inhibitor, has been paid for by
national insurance reimbursement in Taiwan since 2012. In
this study, we have demonstrated that the use of rivarox-
aban and heparin analogs can reduce the incidence of
thrombosis compared with other antithrombotic drugs after
THA or TKA. The expenditure and hospitalization stay were
lower in patients who took rivaroxaban compared with
those who received heparin analogs. Regarding hemorrhage
risk during hospitalization (Table 4), males had higher risks
than females (odds ratio Z 1.487). Use of any antith-
rombotic drug will increase the risk of hemorrhage.
Therefore, we should pay more attention to male patients
who received anticoagulants after undergoing total joint
arthroplasty.
There are several limitations in this study. First, this
study was randomized with millions sampling distribution
and may have sampling bias within the actual population.
Second, this study did not perform a chart review to
determine the actual thrombosis rate. For DRG reimburse-
ment applications, it is possible that the thrombosis code
was not properly keyed in, resulting in a lower thrombosis
rate in patients who did not use antithrombotic agents after
THA and TKA. Third, this study was a retrospective data
analysis; it could only find correlation but not the causality.
Fourth, there might have been some errors in the NHI
database. For example, the coding of diseases might have
been added to the database for reimbursement reasons.
Thus, the endpoints of thrombosis events might not have
been correctly reflected.
Conclusion
In this study, we have demonstrated that the use of
antithrombotic agents, particularly rivaroxaban, a factor Xa
inhibitor, for preventing VTE can reduce the incidence of
thrombosis after THA or TKA compared with other antith-
rombotic drugs (although it should be noted that those who
received rivaroxaban were younger). We also found that
the cost of medication was similar to other antithrombotic
Rivaroxaban in preventing venous thromboembolism 539drugs, and the bleeding risk was similar to that of heparin
analogs. However, further cost-effective and drug safety
studies are required. It is important to consider the cost-
effective principle for the use of antithrombotic drugs in
preventing thromboembolic complications after total joint
surgeries.
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